Abstract: Objective To analyze the applicability of different analgesic schemes in patients with ischemic pain of lower limbs, and to provide reference for clinical medication. Methods Patients with ischemic pain of lower limbs treated between October 1, 2018 and October 31, 2022 were selected as the subjects. The analgesic schemes were evaluated via retrospective analysis. The basic data of patients, usage of analgesic drugs, scores of the visual analogue scale (VAS) of pain and incidence of adverse reaction were analyzed. Results The 71 patients were divided into the opioid group (30 cases), opioid plus non-steroidal anti-inflammatory drugs (NSAIDs) group (32 cases) and sciatic nerve block group (9 cases). There was no significant difference in gender, age, courses of disease, disease complications or smoking status between the three groups (P > 0.05). The VAS score decreased more significantly in the sciatic nerve block group than in the opioid group and opioid combined with NSAIDs group (6.667 ± 1.658 vs 3.567 ± 0.817, t=7. 716, P <0.001; 6.667 ± 1.658 vs 3.938 ± 0.982, t=6. 271, P < 0.001), but there was no significant difference between the opioid group and the opioid combined with NSAIDs group (P > 0.05) or between the three groups (P>0.05) in terms of adverse reactions and safety. Conclusion There are many analgesic regimens for ischemic pain in lower limbs. Compared with opioid alone or opioid combined with NSAIDs, sciatic nerve block can improve pain complaints and VAS scores more significantly and cause fewer adverse reactions, which should be made more accessible.

Key words: ischemic pain of lower limbs, analgesics, opioid plus non-steroidal, anti-inflammatory drugs, sciatic nerve block group, efficacy, adverse drug reactions, safety